Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott M Lippman

Showing results (171-180 of 340) with videos related to

Pageof 34
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2008
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancyHidetoshi Kawaguchi, Adel K El-Naggar, Vali Papadimitrakopoulou, et al.
Iscience|August 16, 2024
Molecular Tumor Board for Unicorns: Outcomes for rare and ultra-rare cancers using an N-of-One personalized treatment strategyBryan H Louie, Shumei Kato, Jordan S Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2012
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemopreventionMichelle A T Hildebrandt, Scott M Lippman, Carol J Etzel, et al.
The New England Journal of Medicine|April 9, 2004
The influence of resection and aneuploidy on mortality in oral leukoplakiaJon Sudbø, Scott M Lippman, J Jack Lee, et al.
Cancer Research|July 19, 2005
Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived productsJeri Kim, Peiying Yang, Milind Suraokar, et al.
JAMA Oncology|June 15, 2018
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid TumorsAaron M Goodman, David Piccioni, Shumei Kato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2009
DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakiaPierre Saintigny, Adel K El-Naggar, Vali Papadimitrakopoulou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2003
An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasiaCharles M Rudin, Ezra E W Cohen, Vassiliki A Papadimitrakopoulou, et al.
Cancer|March 13, 2010
Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancerWilliam N William, Merrill S Kies, Frank V Fossella, et al.
Journal of the National Cancer Institute|December 12, 2024
Optimizing public private partnerships to support clinical cancer researchRoy S Herbst, Gideon Blumenthal, Samir N Khleif, et al.
Pageof 34

Showing results (171-180 of 340) with videos related to

Sort By:
Pageof 34
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2008
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancyHidetoshi Kawaguchi, Adel K El-Naggar, Vali Papadimitrakopoulou, et al.
Iscience|August 16, 2024
Molecular Tumor Board for Unicorns: Outcomes for rare and ultra-rare cancers using an N-of-One personalized treatment strategyBryan H Louie, Shumei Kato, Jordan S Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2012
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemopreventionMichelle A T Hildebrandt, Scott M Lippman, Carol J Etzel, et al.
The New England Journal of Medicine|April 9, 2004
The influence of resection and aneuploidy on mortality in oral leukoplakiaJon Sudbø, Scott M Lippman, J Jack Lee, et al.
Cancer Research|July 19, 2005
Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived productsJeri Kim, Peiying Yang, Milind Suraokar, et al.
JAMA Oncology|June 15, 2018
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid TumorsAaron M Goodman, David Piccioni, Shumei Kato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2009
DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakiaPierre Saintigny, Adel K El-Naggar, Vali Papadimitrakopoulou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2003
An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasiaCharles M Rudin, Ezra E W Cohen, Vassiliki A Papadimitrakopoulou, et al.
Cancer|March 13, 2010
Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancerWilliam N William, Merrill S Kies, Frank V Fossella, et al.
Journal of the National Cancer Institute|December 12, 2024
Optimizing public private partnerships to support clinical cancer researchRoy S Herbst, Gideon Blumenthal, Samir N Khleif, et al.
Pageof 34